RAD51 and cancer: Cells bearing defects in ATM, p53 or RAD51 were particularly sensitive to the mutagenicity provoked by traditional anti-cancer drugs, implying that non-mutagenic therapies like Smac mimetics would be particularly beneficial for patients with germline mutations in DNA damage response genes.